Age-related decline in CD8+ tissue resident memory T cells compromises antitumor immunity.

IF 17 Q1 CELL BIOLOGY
Siyu Pei, Xiuyu Deng, Ruirui Yang, Hui Wang, Jian-Hong Shi, Xueqing Wang, Jia Huang, Yu Tian, Rongjing Wang, Sulin Zhang, Hui Hou, Jing Xu, Qingcheng Zhu, Huan Huang, Jialing Ye, Cong-Yi Wang, Wei Lu, Qingquan Luo, Zhi-Yu Ni, Mingyue Zheng, Yichuan Xiao
{"title":"Age-related decline in CD8<sup>+</sup> tissue resident memory T cells compromises antitumor immunity.","authors":"Siyu Pei, Xiuyu Deng, Ruirui Yang, Hui Wang, Jian-Hong Shi, Xueqing Wang, Jia Huang, Yu Tian, Rongjing Wang, Sulin Zhang, Hui Hou, Jing Xu, Qingcheng Zhu, Huan Huang, Jialing Ye, Cong-Yi Wang, Wei Lu, Qingquan Luo, Zhi-Yu Ni, Mingyue Zheng, Yichuan Xiao","doi":"10.1038/s43587-024-00746-5","DOIUrl":null,"url":null,"abstract":"<p><p>Aging compromises antitumor immunity, but the underlying mechanisms remain elusive. Here, we report that aging impairs the generation of CD8<sup>+</sup> tissue resident memory T (T<sub>RM</sub>) cells in nonlymphoid tissues in mice, thus compromising the antitumor activity of aged CD8<sup>+</sup> T cells, which we also observed in human lung adenocarcinoma. We further identified that the apoptosis regulator BFAR was highly enriched in aged CD8<sup>+</sup> T cells, in which BFAR suppressed cytokine-induced JAK2 signaling by activating JAK2 deubiquitination, thereby limiting downstream STAT1-mediated T<sub>RM</sub> reprogramming. Targeting BFAR either through Bfar knockout or treatment with our developed BFAR inhibitor, iBFAR2, rescued the antitumor activity of aged CD8<sup>+</sup> T cells by restoring T<sub>RM</sub> generation in the tumor microenvironment, thus efficiently inhibiting tumor growth in aged CD8<sup>+</sup> T cell transfer and anti-programmed cell death protein 1 (PD-1)-resistant mouse tumor models. Together, our findings establish BFAR-induced T<sub>RM</sub> restriction as a key mechanism causing aged CD8<sup>+</sup> T cell dysfunction and highlight the translational potential of iBFAR2 in restoring antitumor activity in aged individuals or patients resistant to anti-PD-1 therapy.</p>","PeriodicalId":94150,"journal":{"name":"Nature aging","volume":" ","pages":""},"PeriodicalIF":17.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature aging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s43587-024-00746-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aging compromises antitumor immunity, but the underlying mechanisms remain elusive. Here, we report that aging impairs the generation of CD8+ tissue resident memory T (TRM) cells in nonlymphoid tissues in mice, thus compromising the antitumor activity of aged CD8+ T cells, which we also observed in human lung adenocarcinoma. We further identified that the apoptosis regulator BFAR was highly enriched in aged CD8+ T cells, in which BFAR suppressed cytokine-induced JAK2 signaling by activating JAK2 deubiquitination, thereby limiting downstream STAT1-mediated TRM reprogramming. Targeting BFAR either through Bfar knockout or treatment with our developed BFAR inhibitor, iBFAR2, rescued the antitumor activity of aged CD8+ T cells by restoring TRM generation in the tumor microenvironment, thus efficiently inhibiting tumor growth in aged CD8+ T cell transfer and anti-programmed cell death protein 1 (PD-1)-resistant mouse tumor models. Together, our findings establish BFAR-induced TRM restriction as a key mechanism causing aged CD8+ T cell dysfunction and highlight the translational potential of iBFAR2 in restoring antitumor activity in aged individuals or patients resistant to anti-PD-1 therapy.

与年龄有关的 CD8+ 组织常驻记忆 T 细胞减少会损害抗肿瘤免疫力。
衰老会损害抗肿瘤免疫力,但其潜在机制仍然难以捉摸。在此,我们报告了衰老会损害小鼠非淋巴组织中 CD8+ 组织常驻记忆 T(TRM)细胞的生成,从而损害衰老 CD8+ T 细胞的抗肿瘤活性,我们在人类肺腺癌中也观察到了这一现象。我们进一步发现,凋亡调节因子BFAR在老化CD8+ T细胞中高度富集,其中BFAR通过激活JAK2去泛素化抑制细胞因子诱导的JAK2信号传导,从而限制下游STAT1介导的TRM重编程。通过敲除Bfar或使用我们开发的BFAR抑制剂iBFAR2来靶向BFAR,可以通过恢复肿瘤微环境中TRM的生成来挽救高龄CD8+ T细胞的抗肿瘤活性,从而有效抑制高龄CD8+ T细胞转移和抗程序性细胞死亡蛋白1(PD-1)抗性小鼠肿瘤模型中的肿瘤生长。总之,我们的研究结果确立了 BFAR 诱导的 TRM 限制是导致高龄 CD8+ T 细胞功能障碍的关键机制,并强调了 iBFAR2 在恢复高龄个体或抗 PD-1 治疗耐药患者的抗肿瘤活性方面的转化潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
14.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信